Health-Related Quality of Life and Its Influence Factors in Chinese Patients with Phenylketonuria

Why It Matters

The study reveals socioeconomic and clinical barriers that depress HRQoL in Chinese PKU patients, guiding policymakers and clinicians toward targeted interventions.

Key Takeaways

• Mean EQ-5D utility score 0.91 among Chinese PKU patients
• 62% patients reside in rural areas, low education levels
• Disability and complications significantly reduce health utility scores
• Treatment compliance and discrimination affect self‑rated health VAS
• Annual family income mostly between ¥10k‑¥50k

Pulse Analysis

Phenylketonuria (PKU) remains a rare but lifelong metabolic disorder, requiring strict dietary management to prevent neurocognitive decline. In China, where healthcare access and cultural attitudes differ markedly from Western contexts, understanding patient‑reported outcomes is essential for designing effective support systems. The recent cross‑sectional study provides the first large‑scale insight into how Chinese PKU patients perceive their health, using the globally recognized EQ‑5D tool to benchmark against the broader population.

The findings paint a nuanced picture: while the average health utility score of 0.91 suggests relatively high functioning, it still trails the national norm, indicating room for improvement. Rural residency, limited education, and low household income dominate the demographic profile, underscoring systemic inequities. More critically, statistical models pinpoint disability and medical complications as primary drivers of reduced utility, whereas self‑rated visual analogue scores are sensitive to treatment adherence and experiences of discrimination. These layers of vulnerability highlight that clinical management alone cannot close the HRQoL gap.

For stakeholders, the implications are clear. Health authorities should prioritize integrated care pathways that combine metabolic monitoring with psychosocial support, especially in underserved regions. Insurance schemes could be expanded to cover specialized low‑phenylalanine foods, mitigating financial strain. Moreover, anti‑discrimination initiatives within schools and workplaces can alleviate the stigma that erodes patients' perceived wellbeing. Future research should longitudinally track HRQoL trajectories as new therapies emerge, ensuring that policy decisions remain data‑driven and patient‑centered.